A Prognostic Gene-Expression Signature and Risk Score for Meningioma Recurrence After Resection.

BACKGROUND Prognostic markers for meningioma are needed to risk-stratify patients and guide postoperative surveillance and adjuvant therapy. OBJECTIVE To identify a prognostic gene signature for meningioma recurrence and mortality after resection using targeted gene-expression analysis. METHODS Targeted gene-expression analysis was used to interrogate a discovery cohort of 96 meningiomas and an independent validation cohort of 56 meningiomas with comprehensive clinical follow-up data from separate institutions. Bioinformatic analysis was used to identify prognostic genes and generate a gene-signature risk score between 0 and 1 for local recurrence. RESULTS We identified a 36-gene signature of meningioma recurrence after resection that achieved an area under the curve of 0.86 in identifying tumors at risk for adverse clinical outcomes. The gene-signature risk score compared favorably to World Health Organization (WHO) grade in stratifying cases by local freedom from recurrence (LFFR, P < .001 vs .09, log-rank test), shorter time to failure (TTF, F-test, P < .0001), and overall survival (OS, P < .0001 vs .07) and was independently associated with worse LFFR (relative risk [RR] 1.56, 95% CI 1.30-1.90) and OS (RR 1.32, 95% CI 1.07-1.64), after adjusting for clinical covariates. When tested on an independent validation cohort, the gene-signature risk score remained associated with shorter TTF (F-test, P = .002), compared favorably to WHO grade in stratifying cases by OS (P = .003 vs P = .10), and was significantly associated with worse OS (RR 1.86, 95% CI 1.19-2.88) on multivariate analysis. CONCLUSION The prognostic meningioma gene-expression signature and risk score presented may be useful for identifying patients at risk for recurrence.

[1]  D. Kong,et al.  Forkhead box M1 (FOXM1) transcription factor is a key oncogenic driver of aggressive human meningioma progression , 2020, Neuropathology and applied neurobiology.

[2]  K. Duesing,et al.  DNA Methylation Cancer Biomarkers: Translation to the Clinic , 2019, Front. Genet..

[3]  M. McDermott,et al.  Surgical outcomes after reoperation for recurrent non-skull base meningiomas. , 2019, Journal of neurosurgery.

[4]  Yi-Wen Chang,et al.  SFRPs Are Biphasic Modulators of Wnt-Signaling-Elicited Cancer Stem Cell Properties beyond Extracellular Control. , 2019, Cell reports.

[5]  John F. Magnotti,et al.  Molecular profiling predicts meningioma recurrence and reveals loss of DREAM complex repression in aggressive tumors , 2019, Proceedings of the National Academy of Sciences.

[6]  Damian Szklarczyk,et al.  STRING v11: protein–protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets , 2018, Nucleic Acids Res..

[7]  Jill S Barnholtz-Sloan,et al.  CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015. , 2018, Neuro-oncology.

[8]  Li Yang,et al.  Regulation of the master regulator FOXM1 in cancer , 2018, Cell Communication and Signaling.

[9]  Youngwoon Choi,et al.  P02.01 Altered FoxM1 expression contributes to the meningioma malignancy and can be a critical target for the tumor progression , 2018, Neuro-Oncology.

[10]  M. Taphoorn,et al.  OS4.2 The long-term disease burden of meningioma patients: results on health-related quality of life, cognitive function, anxiety and depression , 2018, Neuro-Oncology.

[11]  Virginia G Kaklamani,et al.  Adjuvant Chemotherapy Guided by a 21‐Gene Expression Assay in Breast Cancer , 2018, The New England journal of medicine.

[12]  Qi Yu,et al.  GNE: a deep learning framework for gene network inference by aggregating biological information , 2018, bioRxiv.

[13]  M. McDermott,et al.  Histopathological features predictive of local control of atypical meningioma after surgery and adjuvant radiotherapy. , 2018, Journal of neurosurgery.

[14]  Susan M. Chang,et al.  Comprehensive Molecular Profiling Identifies FOXM1 as a Key Transcription Factor for Meningioma Proliferation , 2018, Cell reports.

[15]  M. McDermott,et al.  Salvage therapy outcomes for atypical meningioma , 2018, Journal of Neuro-Oncology.

[16]  K. Aldape,et al.  A gene expression signature predicts recurrence-free survival in meningioma , 2018, Oncotarget.

[17]  P. Brastianos,et al.  Advances in meningioma genetics: novel therapeutic opportunities , 2018, Nature Reviews Neurology.

[18]  S. Santagata,et al.  BAP1 mutations in high-grade meningioma: implications for patient care. , 2017, Neuro-oncology.

[19]  O. Delattre,et al.  MYBL2 (B-Myb): a central regulator of cell proliferation, cell survival and differentiation involved in tumorigenesis , 2017, Cell Death & Disease.

[20]  Martin Sill,et al.  DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. , 2017, The Lancet. Oncology.

[21]  Y. Garces,et al.  The Risk of Radiation-Induced Tumors or Malignant Transformation After Single-Fraction Intracranial Radiosurgery: Results Based on a 25-Year Experience. , 2017, International journal of radiation oncology, biology, physics.

[22]  David T. W. Jones,et al.  Global epigenetic profiling identifies methylation subgroups associated with recurrence-free survival in meningioma , 2017, Acta Neuropathologica.

[23]  Peter Horak,et al.  Integrating next-generation sequencing into clinical oncology: strategies, promises and pitfalls , 2016, ESMO Open.

[24]  D. Shrieve,et al.  Adjuvant radiotherapy for atypical meningiomas. , 2016, Journal of neurosurgery.

[25]  R. Beroukhim,et al.  Genomic landscape of intracranial meningiomas. , 2016, Journal of neurosurgery.

[26]  Mark W. Youngblood,et al.  Recurrent somatic mutations in POLR2A define a distinct subset of meningiomas , 2016, Nature Genetics.

[27]  Rory K. J. Murphy,et al.  Radiation Therapy for Residual or Recurrent Atypical Meningioma: The Effects of Modality, Timing, and Tumor Pathology on Long-Term Outcomes. , 2016, Neurosurgery.

[28]  K. Aldape,et al.  TERT Promoter Mutations and Risk of Recurrence in Meningioma. , 2016, Journal of the National Cancer Institute.

[29]  R. Beroukhim,et al.  Extent of resection and overall survival for patients with atypical and malignant meningioma , 2015, Cancer.

[30]  K. L. Silva,et al.  FOXM1 targets XIAP and Survivin to modulate breast cancer survival and chemoresistance. , 2015, Cellular signalling.

[31]  Charmaine D. Wilson,et al.  Mitotic Index is an Independent Predictor of Recurrence‐Free Survival in Meningioma , 2015, Brain pathology.

[32]  Mark D. Johnson,et al.  Adjuvant radiation therapy, local recurrence, and the need for salvage therapy in atypical meningioma. , 2014, Neuro-oncology.

[33]  P. Eldridge,et al.  Long-term survival analysis of atypical meningiomas: survival rates, prognostic factors, operative and radiotherapy treatment , 2014, Acta Neurochirurgica.

[34]  C. James,et al.  Adjuvant radiotherapy for atypical and malignant meningiomas: a systematic review. , 2014, Neuro-oncology.

[35]  D. Watson,et al.  Analytical validation of the Oncotype DX prostate cancer assay – a clinical RT-PCR assay optimized for prostate needle biopsies , 2013, BMC Genomics.

[36]  P. Jacoby,et al.  Morbidity in survivors of child and adolescent meningioma , 2013, Cancer.

[37]  Murim Choi,et al.  Genomic Analysis of Non-NF2 Meningiomas Reveals Mutations in TRAF7, KLF4, AKT1, and SMO , 2013, Science.

[38]  C. Brennan,et al.  The role of radiotherapy following gross-total resection of atypical meningiomas. , 2012, Journal of neurosurgery.

[39]  Juan F. García,et al.  Genetic Alterations Associated With Progression and Recurrence in Meningiomas , 2012, Journal of neuropathology and experimental neurology.

[40]  A. von Deimling,et al.  Long-term outcome after radiotherapy in patients with atypical and malignant meningiomas--clinical results in 85 patients treated in a single institution leading to optimized guidelines for early radiation therapy. , 2012, International journal of radiation oncology, biology, physics.

[41]  A. Kallioniemi.  Bone morphogenetic protein 4-a fascinating regulator of cancer cell behavior. , 2012, Cancer genetics.

[42]  W. Vandertop,et al.  Impaired survival and long-term neurological problems in benign meningioma. , 2012, Neuro-oncology.

[43]  J. Cuzick,et al.  Prognostic value of a cell cycle progression signature for prostate cancer death in a conservatively managed needle biopsy cohort , 2012, British Journal of Cancer.

[44]  E. Rushing,et al.  Meningiomas in children and adolescents: a meta-analysis of individual patient data. , 2011, The Lancet. Oncology.

[45]  E. Claus,et al.  Treatment and survival of patients with nonmalignant intracranial meningioma: results from the Surveillance, Epidemiology, and End Results Program of the National Cancer Institute. Clinical article. , 2011, Journal of neurosurgery.

[46]  A. Bosserhoff,et al.  CTGF is overexpressed in malignant melanoma and promotes cell invasion and migration , 2011, British Journal of Cancer.

[47]  Gaël Varoquaux,et al.  Scikit-learn: Machine Learning in Python , 2011, J. Mach. Learn. Res..

[48]  Arie Perry,et al.  Identification of Gene Markers Associated With Aggressive Meningioma by Filtering Across Multiple Sets of Gene Expression Arrays , 2011, Journal of neuropathology and experimental neurology.

[49]  Juan F. García,et al.  Differential expression profiling analyses identifies downregulation of 1p, 6q, and 14q genes and overexpression of 6p histone cluster 1 genes as markers of recurrence in meningiomas. , 2010, Neuro-oncology.

[50]  I. Salmon,et al.  Gene Expression Profiling of the Hedgehog Signaling Pathway in Human Meningiomas , 2010, Molecular medicine.

[51]  Soheil Shams,et al.  Genomic Landscape of Meningiomas , 2009, Brain pathology.

[52]  J. Nitiss.  Targeting DNA topoisomerase II in cancer chemotherapy , 2009, Nature Reviews Cancer.

[53]  Christoph Seifarth,et al.  Repression of BIRC5/survivin by FOXO3/FKHRL1 sensitizes human neuroblastoma cells to DNA damage-induced apoptosis. , 2009, Molecular biology of the cell.

[54]  Ralf Herwig,et al.  ConsensusPathDB—a database for integrating human functional interaction networks , 2008, Nucleic Acids Res..

[55]  Jordi Bruna,et al.  Ki‐67 proliferative index predicts clinical outcome in patients with atypical or anaplastic meningioma , 2007, Neuropathology : official journal of the Japanese Society of Neuropathology.

[56]  K. Strebhardt,et al.  Cyclin B1 depletion inhibits proliferation and induces apoptosis in human tumor cells , 2004, Oncogene.

[57]  J. Hainfellner,et al.  Progesterone-receptor index in meningiomas: correlation with clinico-pathological parameters and review of the literature , 2004, Neurosurgical Review.

[58]  R. Tibshirani,et al.  Diagnosis of multiple cancer types by shrunken centroids of gene expression , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[59]  B. Scheithauer,et al.  The prognostic significance of MIB‐1, p53, and DNA flow cytometry in completely resected primary meningiomas , 1998, Cancer.

[60]  J M Buatti,et al.  Benign meningiomas: primary treatment selection affects survival. , 1997, International journal of radiation oncology, biology, physics.

[61]  M. E. Ruaro,et al.  The growth arrest-specific gene, gas1, is involved in growth suppression , 1992, Cell.

[62]  E. Claus,et al.  Treatment and survival of patients with nonmalignant intracranial meningioma: results from the Surveillance, Epidemiology, and End Results Program of the National Cancer Institute , 2012 .